Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 5Phase NA 3Phase 3 3Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Multiple Myeloma 70Leukemia, Myeloid, Acute 70Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Non-Hodgkin 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma 56Melanoma 52Leukemia 52Breast Neoplasms 49Burkitt Lymphoma 48Myelodysplastic Syndromes 44Recurrence 41Lymphoma, Follicular 41Lymphoma, B-Cell 38Lymphoma, Mantle-Cell 37Ovarian Neoplasms 32Neuroblastoma 32Lymphoma, B-Cell, Marginal Zone 27Sarcoma 26Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Hodgkin Disease 24Neoplasm Metastasis 23Triple Negative Breast Neoplasms 18Carcinoma, Renal Cell 18Neoplasms, Plasma Cell 17Hematologic Neoplasms 17Leukemia, Myelomonocytic, Chronic 16Colorectal Neoplasms 16

Interventions

Trastuzumab 8Paclitaxel 7Taxes 6Lapatinib 6Docetaxel 5veliparib 3Tamoxifen 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3sargramostim 2liposomal doxorubicin 2ixabepilone 2cediranib 2Vorinostat 2Vinorelbine 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Mifepristone 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Granulocyte-Macrophage Colony-Stimulating Factor 2Goserelin 2Gemcitabine 2Filgrastim 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms, Male × Cyclophosphamide × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01219907 2013-05-17

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

University of Washington

Phase 1 Withdrawn
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡